X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Freddie, Fannie, pharma and more... - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jul 15, 2008

    Freddie, Fannie, pharma and more...

    Freddie and Fannie cast their net wide
    The predicament faced by the US' largest mortgage financiers Freddie Mac and Fannie Mae continued to have a dampening effect on markets around the world with most of the Asian indices ending in the red on Monday. The weight of the subprime crisis was too much to bear for these two institutions and last week saw the stock of these two companies plummet by 18% and 16% respectively in a single day. In the latest development, the Bush administration has announced plans to bail out these institutions by asking the Congress to approve a package that would infuse a staggering sum of around US$ 300 bn into them. After the unraveling of the subprime crisis, this is the second time that the government has come to the aid of financial institutions, the first one being its involvement in bailing out Bear Sterns out of trouble. And this has again brought to the fore the extent of the credit crisis, which appears to be much deeper than what was envisaged earlier.

    Not surprising then, that the Asian markets reacted negatively to this development given that a majority of them rely on exports to the world's largest economy. As if this is not enough, high oil prices and steep inflation is only adding more fuel to the fire.

    Food woes continue; this time it is oilseeds
    Insufficient rainfall is expected to render India vulnerable when it comes to oilseeds. India is the world's second largest buyer of oilseeds after China and a spell of dry weather in the biggest growing regions of the country means that it will have to import the same. India of late has seen its inflation surge within a striking distance of 12% and needs to boost cooking oil supplies to temper prices. As per reports on Bloomberg, increased imports of oilseeds by India will support prices of palm and soybean oils, which already reached record levels last year. Statistics further reveal two not so enthusing facts - one is that India's edible oil imports rose to 13% in the eight months ended June as compared to the corresponding period last year; the second one being the fact that the June-September monsoon rains, which account for four- fifths of the nation's annual rainfall, was 20% less than normal in the week ended July 9. This certainly does not bode well for the Indian economy, which is also reeling under high oil prices.

  • Also read - Food Vs Fuel: The argument continues...

    Ranbaxy is making headlines...
    ...but for the wrong reasons this time! The pharmaceutical giant was on the front page of leading news dailies earlier when it announced that the company's promoters are selling their stake to the Japanese pharma company Daiichi for a sum between US$ 3.4 bn to US$ 4.6 bn. This time, Ranbaxy is in the news on allegations made by the US FDA that the company has forged crucial data in a bid to get marketing approvals for its drugs in the US market. Readers would do well to recall the fact that the company was at the receiving end last year when Ranbaxy's Paonta Sahib facility was not complying with the standards set by the US FDA. This had led to a shut down of the plant and a delay in the launch of some of its products in the US, including 'Pravastatin 80 mg' for which Ranbaxy had a 180-day exclusivity.

    The US FDA's allegations may not go down well with the new owners of the company, Daiichi. While Ranbaxy has denied these allegations, in the event that they are proven to be true, then it will be detrimental to India's largest pharmaceutical company, for which the US contributes around 24% to total revenues. Not to mention the vast sum that the company may have to dole out in potential damages. The stock was duly pummeled on Monday, closing the trading session with losses of 11%, amply demonstrating that the stockmarkets did not see this development in a favourable light.

  • Also read - Ranbaxy sells out to Daiichi: Our view

     

     

    Equitymaster requests your view! Post a comment on "Freddie, Fannie, pharma and more...". Click here!

      
     

    More Views on News

    How to Ride Alongside India's Best Fund Managers (The 5 Minute Wrapup)

    Jun 10, 2017

    Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.

    Why NOW Is the WORST Time for Index Investing (The 5 Minute Wrapup)

    Aug 18, 2017

    Buying the index now will hardly help make money in stocks even in ten years.

    Trump Takes a Beating (Vivek Kaul's Diary)

    Aug 18, 2017

    Donald J Trump, a wrasslin' fan, took a 'Holy Sh*t!' blow on Tuesday.

    How To Read Your Mutual Fund Account Statement Correctly (Outside View)

    Aug 17, 2017

    PersonalFN simplifies the mutual fund account statement for you.

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process) (The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
  •  

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE SENSEX


    Aug 18, 2017 (Close)

    MARKET STATS